Frederique Menzaghi Ph.D., Chief Scientific Officer, SVP-R&D at Cara Therapeutics, Inc. (CARA), sold 2,114 shares at $10.29 ($22K) on 2022-02-25, disclosed to the SEC on 2022-03-01.
Scheduled sale ($22k) by Chief Scientific Officer, SVP-R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| CARA | SELL | 2023-03-07 | $132K | — | Filing → |
| CARA | SELL | 2022-12-23 | $40K | — | Filing → |
| CARA | SELL | 2022-04-05 | $21K | — | Filing → |